{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:34:42Z","timestamp":1760060082805,"version":"build-2065373602"},"reference-count":36,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Pleural mesothelioma (PM) is a type of cancer that is difficult to diagnose and treat. Patients may have vastly varying prognoses, and prognostic factors may help guide the clinical approach. As a recently identified biomarker, the pan-Immune-Inflammation-Value (PIV) is a simple, comprehensive, and peripheral blood cell-based biomarker. Methods: The present study represents a retrospective observational analysis carried out within a single-center setting. Ninety-five patients with PM stages I\u2013IV were enrolled in the study. We analyzed the correlation between patients\u2019 demographic characteristics, clinicopathological factors such as histological subtypes, surgery status, tumor thickness, blood-based parameters, and treatment options with their prognoses. PIV was calculated by the following formula: (neutrophil count \u00d7 monocyte count \u00d7 platelet count)\/lymphocyte count. Additionally, blood-based parameters were used to calculate the platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and systemic immune inflammation index (SII). Results: We categorized the patients into two groups, low PIV group (PIV \u2264 732.3) and high PIV group (PIV &gt; 732.3) according to the determined cut-off value, which was defined as the median. It was revealed that high PIV was associated with poor survival outcomes. The median follow-up period was 15.8 months (interquartile range, IQR, 7.1 to 29.8 months). The median overall survival (OS) was significantly longer in patients in the low PIV group (median 29.8 months, 95% confidence interval (CI), 15.6 to 44) than the high PIV group (median 14.7 months, 95% CI, 10.8 to 18.6 p &lt; 0.001). Furthermore, the study revealed that patients with low PIV, NLR, and SII values were more likely to be eligible for surgery and were diagnosed at earlier stages. Additionally, these markers were identified as potential predictors of disease-free survival (DFS) in the surgical cohort and of treatment response across the entire patient population. Conclusions: In addition to well-established clinical factors such as stage, histologic subtype, resectability, and Eastern Cooperative Oncology Group (ECOG) performance status (PS), PIV emerged as an independent and significant prognostic factor of overall survival (OS) in patients with PM. Moreover, PIV also demonstrated a remarkable independent prognostic value for disease-free survival (DFS) in this patient population. Additionally, some clues are provided for conditions such as treatment responses, staging, and suitability for surgery. As such, in this cohort, it has outperformed the other blood-based markers based on our findings. Given its ease of calculation and cost-effectiveness, PIV represents a promising and practical prognostic tool in the clinical management of pleural mesothelioma. It can be easily calculated using routinely available laboratory parameters for every cancer patient, requiring no additional cost or complex procedures, thus facilitating its integration into everyday clinical practice.<\/jats:p>","DOI":"10.3390\/jcm14155467","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T08:46:55Z","timestamp":1754383615000},"page":"5467","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Promising Prognostic Indicator for Pleural Mesothelioma: Pan-Immuno-Inflammation Value"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1465-4131","authenticated-orcid":false,"given":"Serkan","family":"Ya\u015far","sequence":"first","affiliation":[{"name":"Department of Medical Oncology TR, Hacettepe University Cancer Institute, 06100 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5848-3381","authenticated-orcid":false,"given":"Feride","family":"Y\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology TR, Hacettepe University Cancer Institute, 06100 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1860-7965","authenticated-orcid":false,"given":"\u00d6mer Denizhan","family":"Tatar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine TR, Sinop Turkeli State Hospital, 57900 Sinop, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3060-377X","authenticated-orcid":false,"given":"Hasan \u00c7a\u011fr\u0131","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology TR, Nigde Omer Halisdemir Training and Research Hospital, 51100 Nigde, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafer","family":"Ar\u0131k","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology TR, Hacettepe University Cancer Institute, 06100 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015euayib","family":"Yal\u00e7\u0131n","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology TR, Hacettepe University Cancer Institute, 06100 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Erman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology TR, Hacettepe University Cancer Institute, 06100 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Brims, F. (2021). Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma. Cancers, 13.","DOI":"10.3390\/cancers13164194"},{"key":"ref_2","first-page":"e20210129","article-title":"Malignant pleural mesothelioma: An update","volume":"47","author":"Hajj","year":"2021","journal-title":"J. Bras. Pneumol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Metintas, S., Batirel, H.F., Bayram, H., Yilmaz, U., Karadag, M., Ak, G., and Metintas, M. (2017). Turkey National Mesothelioma Surveillance and Environmental Asbestos Exposure Control Program. Int. J. Environ. Res. Public Health, 14.","DOI":"10.3390\/ijerph14111293"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","article-title":"Perspectives on the Treatment of Malignant Pleural Mesothelioma","volume":"385","author":"Janes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.21.01567","article-title":"New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options","volume":"40","author":"Tsao","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): A phase 3 randomised controlled trial","volume":"12","author":"Lim","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: Clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.athoracsur.2024.02.022","article-title":"Impact of Operation on Disease Progression and Survival of Patients With Pleural Mesothelioma","volume":"118","author":"Nakamura","year":"2024","journal-title":"Ann. Thorac. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sorino, C., Mondoni, M., Marchetti, G., Agati, S., Inchingolo, R., Mei, F., Flamini, S., Lococo, F., and Feller-Kopman, D. (2023). Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers. J. Clin. Med., 12.","DOI":"10.3390\/jcm12227006"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","article-title":"BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study","volume":"17","author":"Louw","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.2174\/1381612821666150514105741","article-title":"Inflammation fuels tumor progress and metastasis","volume":"21","author":"Liu","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1186\/s12967-025-06583-3","article-title":"Targeting inflammation in cancer therapy: From mechanistic insights to emerging therapeutic approaches","volume":"23","author":"Bakrim","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Di Ceglie, I., Carnevale, S., Rigatelli, A., Grieco, G., Molisso, P., and Jaillon, S. (2024). Immune cell networking in solid tumors: Focus on macrophages and neutrophils. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1341390"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Saeed, A.F. (2025). Tumor-Associated Macrophages: Polarization, Immunoregulation, and Immunotherapy. Cells, 14.","DOI":"10.3390\/cells14100741"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zhao, J., Huang, A., Zeller, J., Peter, K., and McFadyen, J.D. (2023). Decoding the role of platelets in tumour metastasis: Enigmatic accomplices and intricate targets for anticancer treatments. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1256129"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Lopresti, L., Tatangelo, V., Baldari, C.T., and Patrussi, L. (2024). Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: A new frontier for precision anti-cancer therapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1418527"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Feng, F., Zheng, G., Wang, Q., Liu, S., Liu, Z., Xu, G., Wang, F., Guo, M., Lian, X., and Zhang, H. (2018). Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer. BMC Gastroenterol., 18.","DOI":"10.1186\/s12876-018-0877-9"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101338","DOI":"10.1016\/j.tranon.2021.101338","article-title":"The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor","volume":"17","author":"Chen","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1007\/s00595-021-02448-6","article-title":"The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I-III colorectal cancer patients undergoing surgery","volume":"52","author":"Sato","year":"2022","journal-title":"Surg. Today"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Sahin, A.B., Cubukcu, E., Ocak, B., Deligonul, A., Oyucu Orhan, S., Tolunay, S., Gokgoz, M.S., Cetintas, S., Yarbas, G., and Senol, K. (2021). Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-94184-7"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12957-024-03595-z","article-title":"Pan-immune-inflammation value as a novel prognostic biomarker for digestive system cancers: A meta-analysis","volume":"22","author":"Yu","year":"2024","journal-title":"World J. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jtho.2024.03.007","article-title":"The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for Revisions of the \u201cT\u201d Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma","volume":"19","author":"Gill","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.2217\/bmm-2020-0717","article-title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer","volume":"15","author":"Abda","year":"2021","journal-title":"Biomark. Med."},{"key":"ref_27","first-page":"3240","article-title":"Correlation of serum NLR, PLR and HALP with efficacy of neoadjuvant chemotherapy and prognosis of triple-negative breast cancer","volume":"14","author":"Lou","year":"2022","journal-title":"Am. J. Transl. Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Huang, Y., Chen, Y., Zhu, Y., Wu, Q., Yao, C., Xia, H., and Li, C. (2021). Postoperative Systemic Immune-Inflammation Index (SII): A Superior Prognostic Factor of Endometrial Cancer. Front. Surg., 8.","DOI":"10.3389\/fsurg.2021.704235"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s11523-021-00819-0","article-title":"The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy","volume":"16","author":"Fuca","year":"2021","journal-title":"Target. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41416-020-0894-7","article-title":"The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: Results from a pooled-analysis of the Valentino and TRIBE first-line trials","volume":"123","author":"Fuca","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jtho.2021.06.014","article-title":"Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma","volume":"16","author":"Yeap","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/JTO.0b013e31822a3740","article-title":"Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy","volume":"6","author":"Kao","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5505\/aot.2021.58815","article-title":"Potential Novel Prognostic Factors in Malign Mesothelioma: Systemic Inflammatory Indices (SII) & Albumin-to-Globulin Ratio (AGR)","volume":"54","author":"Karakaya","year":"2021","journal-title":"Acta Oncol. Tur."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.2147\/CMAR.S201269","article-title":"High systemic immune-inflammation index represents an unfavorable prognosis of malignant pleural mesothelioma","volume":"11","author":"Ma","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/JTO.0b013e31823f45c1","article-title":"Inflammation-based prognostic indices in malignant pleural mesothelioma","volume":"7","author":"Pinato","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_36","first-page":"2340","article-title":"Prognostic significance of inflammation scores in malignant mesothelioma","volume":"28","author":"Mutlu","year":"2024","journal-title":"Eur. Rev. Med. Pharmacol. Sci."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5467\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:22:28Z","timestamp":1760034148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":36,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jcm14155467"],"URL":"https:\/\/doi.org\/10.3390\/jcm14155467","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,8,4]]}}}